16
Oct 2025
Latest News

ScinoPharm Taiwan Hosts Healing Art Forum in Partnership with Formosa Cancer Foundation

Share:

ScinoPharm Taiwan recently held its 16th annual ScinoPharm Art Forum, a long-standing public art and cultural lecture series dedicated to enriching lives through art and dialogue. This year’s theme, "Reading: The Gentle Remedy." featured renowned author Mr. Eric Wu, who shared heartfelt reflections on how reading can provide strength, comfort, and personal growth.
The event coincided with Breast Cancer Awareness Month in October, and for the first time, ScinoPharm collaborated with the Formosa Cancer Foundation to invite cancer patients and their families to participate. Together, they created a heartwarming and healing experience that blended art, compassion, and community support.


As a leading pharmaceutical company specializing in oncology, ScinoPharm Taiwan is recognized for its robust R&D capabilities and world-class manufacturing standards. The company’s portfolio covers a wide range of cancer therapies, including products addressing hormone receptor-positive breast cancer, which accounts for 60–70% of all breast cancer cases. In alignment with Taiwan’s National Health Insurance Administration (NHIA) policy to strengthen the resilience of domestic drug supply, ScinoPharm continues to leverage its technical expertise to expand local formulation development—enhancing accessibility and providing high-quality treatment options for patients in Taiwan.


"For many years, ScinoPharm has been devoted to developing cancer therapies grounded in science and quality, with confidence and care, to safeguard life and fulfill our promise of health," said Susan Lu, General Manager of ScinoPharm Taiwan. "This year marks the 16th year of our Art Forum initiative. By integrating art with social purpose, we aim to extend our care to those who need it most—fulfilling our brand spirit For every Life. With every trust. We will continue to advance our mission through both pharmaceutical expertise and public engagement, promoting positive and meaningful social impact."

Related Information

04
Nov 2025
Latest News

ScinoPharm Taiwan 15th in 2025 CSR “Small Giants”

Honored as a 2025 CSR “Small Giants” top 15 company by CommonWealth Magazine.

Read More
19
Dec 2024
Latest News

ScinoPharm Partners with Handa Pharmaceuticals to Advance 505(b)(2) Drug Development

ScinoPharm Taiwan, Ltd. today announced a strategic investment in Handa Pharmaceuticals, Inc., marking the beginning of a collaboration to share R&D resources and leverage complementary strengths in advancing 505(b)(2) new drug development. This partnership will drive efforts in research, clinical trials, regulatory approvals, and product commercialization.

Read More
20
Nov 2024
Latest News

ScinoPharm Taiwan Achieves Zero-Deficiency Record in ANVISA Inspection, Expanding Its Presence in Emerging Markets

ScinoPharm Taiwan (SPT) (stock code 1789) has not only solidified its position in the US and EU pharmaceutical markets, but is continuing to extend its reach into promising emerging markets, demonstrating its commitment to expand its global footprint.

Read More

我們使用 Cookie 以允許我們網站的正常工作、個性化設計內容和廣告、提供社交媒體功能並分析流量。我們還同社交媒體、廣告和分析合作夥伴分享有關您使用我們網站的信息

Manage Cookies

Privacy preferences

我們使用 Cookie 以允許我們網站的正常工作、個性化設計內容和廣告、提供社交媒體功能並分析流量。我們還同社交媒體、廣告和分析合作夥伴分享有關您使用我們網站的信息

Privacy Policy

Manage preferences

Necessary cookie

Always on

網站運行離不開這些 Cookie 且您不能在系統中將其關閉。通常僅根據您所做出的操作(即服務請求)來設置這些 Cookie,如設置隱私偏好、登錄或填充表格。您可以將您的瀏覽器設置為阻止或向您提示這些 Cookie,但可能會導致某些網站功能無法工作。